abstract |
The invention relates to a pharmaceutical combination comprising an HMG-Co-A reductase inhibitor, especially fluvastatinor pitavastatin or a pharmaceutically acceptable salt thereof and mTOR inhibiting agent, e.g. rapamycin or a rapamycin derivative . |